“JOURNAL OF SCIENCE-INNOVATIVE RESEARCH IN
UZBEKISTAN” JURNALI
VOLUME 2, ISSUE 9, 2024. SEPTEMBER
ResearchBib Impact Factor: 9.654/2024 ISSN 2992-8869
81
BOLALARDA BRONXIAL ASTMANING KLINIK, IMMUNOLOGIK
VA MIKROBIOLOGIK ASPEKTLARI. OLIB BORISH TAKTIKASINI
OPTIMALLASHTIRISH
Urumboyeva Zamira Olimjonovna
Gospital pediatriya kafedrasi assistenti
Andijon davlat tibbiyot instituti
Annotatsiya:
Maqola bolalarda bronxial astmaning klinik, immunologik va
mikrobiologik aspektlarini o‘rganish hamda davolash taktikasini optimallashtirishga
bag‘ishlangan. Klinika, immunologiya va mikrobiologiya sohalaridagi tekshiruvlar
asosida bronxial astmaning patogenezi, rivojlanish omillari va davolash usullari
tahlil qilingan. Maqolaning asosiy maqsadi — bolalarda bronxial astmani samarali
davolash uchun klinik, immunologik va mikrobiologik tekshiruvlarga asoslangan
davolash taktikasini ishlab chiqish. Kasallikning erta diagnostikasi va individual
davolash yondashuvlarini ishlab chiqish orqali astmani nazorat qilish va bolalar
hayotini yaxshilashga erishish. Tadqiqot natijalariga ko‘ra, astma bolalarda nafas
yo‘llarining surunkali yallig‘lanishi va immunologik buzilishlar bilan bog‘liq. IgE
antitanalari va T-hujayra reaksiyalarining kuchayishi astma rivojlanishining asosiy
omillari sifatida qayd etildi. Mikrobiologik infeksiyalar kasallik xurujlarini
kuchaytirishi aniqlangan. Individual yondashuvlar, immunoterapiya va infeksiyaga
qarshi davolash astma xurujlarini kamaytirishga yordam berdi. Ushbu maqola
bolalar bronxial astmasining klinik, immunologik va mikrobiologik aspektlarini
integratsiyalab,
davolash
taktikasini
yangicha
yondashuvlar
bilan
takomillashtirishni taklif etadi.
Kalit so’zlar:
Bronxial astma, bolalar, klinik belgilar, immunologik
mexanizmlar, mikrobiologik muhit, diagnostika, terapiya, individualizatsiya,
optimallashtirish, strategiyalar
Аннотация:
Статья
посвящена
изучению
клинических,
иммунологических и микробиологических аспектов бронхиальной астмы у
детей, а также оптимизации тактики лечения. На основе исследований в
областях клиники, иммунологии и микробиологии был проведен анализ
“JOURNAL OF SCIENCE-INNOVATIVE RESEARCH IN
UZBEKISTAN” JURNALI
VOLUME 2, ISSUE 9, 2024. SEPTEMBER
ResearchBib Impact Factor: 9.654/2024 ISSN 2992-8869
82
патогенеза, факторов развития и методов лечения бронхиальной астмы.
Основная цель статьи — разработка тактики лечения, основанной на
клинических, иммунологических и микробиологических исследованиях для
эффективного лечения бронхиальной астмы у детей. Достижение контроля
над астмой и улучшение качества жизни детей возможно за счет ранней
диагностики и индивидуальных подходов к лечению. Согласно результатам
исследований, астма у детей связана с хроническим воспалением дыхательных
путей и нарушениями в иммунной системе. Повышение уровня антител IgE и
усиление реакций Т-клеток выделены как основные факторы развития астмы.
Было установлено, что микробиологические инфекции усиливают приступы
заболевания. Индивидуальные подходы, иммунная терапия и антимикробное
лечение способствуют уменьшению частоты приступов астмы. Данная статья
предлагает усовершенствовать тактику лечения бронхиальной астмы у детей
путем интеграции клинических, иммунологических и микробиологических
аспектов.
Ключевые слова:
бронхиальная астма, дети, клинические признаки,
иммунологические механизмы, микробиологическая среда, диагностика,
терапия, индивидуализация, оптимизация, стратегии.
Abstract:
The article is dedicated to the study of the clinical, immunological,
and microbiological aspects of bronchial asthma in children, as well as the
optimization of treatment strategies. Based on research in the fields of clinical
medicine, immunology, and microbiology, an analysis of the pathogenesis,
development factors, and treatment methods for bronchial asthma was conducted.
The main goal of the article is to develop a treatment strategy based on clinical,
immunological, and microbiological studies for the effective treatment of bronchial
asthma in children. Achieving asthma control and improving the quality of life in
children is possible through early diagnosis and individualized treatment
approaches. According to the research findings, asthma in children is associated with
chronic inflammation of the airways and immune system disorders. The increase in
IgE anti div levels and the intensification of T-cell responses are identified as key
factors in the development of asthma. It has been found that microbiological
“JOURNAL OF SCIENCE-INNOVATIVE RESEARCH IN
UZBEKISTAN” JURNALI
VOLUME 2, ISSUE 9, 2024. SEPTEMBER
ResearchBib Impact Factor: 9.654/2024 ISSN 2992-8869
83
infections exacerbate asthma attacks. Individualized approaches, immunotherapy,
and antimicrobial treatment contribute to reducing the frequency of asthma attacks.
This article proposes improving the treatment strategy for bronchial asthma in
children by integrating clinical, immunological, and microbiological aspects.
Key words:
bronchial asthma, children, clinical signs, immunological
mechanisms, microbiological environment, diagnosis, therapy, individualization,
optimization, strategies.
KIRISH:
Bolalarda bronxial astma nafaqat keng tarqalgan kasallik, balki u
sog‘liq uchun jiddiy muammolarni keltirib chiqaradigan surunkali nafas olish tizimi
kasalligi hisoblanadi [1]. Jahon sog‘liqni saqlash tashkiloti (JSST) ma'lumotlariga
ko‘ra, bolalar o‘rtasida astma ko‘rsatkichlari ortib borayotgani sababli unga erta
tashxis qo’yish va samarali davolash yondashuvlarini ishlab chiqish muhim
ahamiyatga ega. Astma bolalar hayotining sifatiga jiddiy ta’sir ko‘rsatadi, shu
jumladan, ularning o‘qish faoliyati, sport bilan shug‘ullanish imkoniyati va umumiy
rivojlanishiga to‘sqinlik qiladi [22]. Ushbu kasallikning samarali boshqarilishi va
davolashning optimallashtirilishi pediatriya va pulmonologiya sohalarida dolzarb
vazifa sifatida kun tartibida turibdi [4]. Bronxial astmaning klinik va immunologik
aspektlari bo‘yicha olib borilgan ko‘plab tadqiqotlar mavjud bo‘lsa-da,
mikrobiologik omillarning kasallik rivojlanishidagi ro’li va ularning davolash
jarayoniga ta’siri kamroq o‘rganilgan [23]. Tadqiqotning yangiligi shundaki, ushbu
maqola bolalarda bronxial astmani o‘rganishda klinik, immunologik va
mikrobiologik omillarni birlashtiradi va davolash taktikasini optimallashtirish uchun
yangi yondashuvlarni taklif etadi. Mikrobiologik muhit va uning astmaga ta’sirini
chuqur tahlil qilish orqali davolash strategiyasini yaxshilash mumkinligi yangicha
yondashuvlarni o‘z ichiga oladi [3]. Maqolaning asosiy maqsadi — bolalarda
bronxial astmaning klinik, immunologik va mikrobiologik jihatlarini chuqur
o‘rganish orqali kasallikni samarali davolash va nazorat qilish usullarini
takomillashtirish.
Tadqiqot
diagnostika
va
davolash
taktikasini
individualizatsiyalashga qaratilgan bo‘lib, astmani erta bosqichda aniqlash va
bolalarga xos davolash usullarini ishlab chiqishni maqsad qiladi [4]. Bolalarda
bronxial astma rivojlanishining klinik ko‘rinishlarini tahlil qilish. Immunologik
mexanizmlar va ularning astma rivojlanishiga ta’sirini o‘rganish [9]. Mikrobiologik
“JOURNAL OF SCIENCE-INNOVATIVE RESEARCH IN
UZBEKISTAN” JURNALI
VOLUME 2, ISSUE 9, 2024. SEPTEMBER
ResearchBib Impact Factor: 9.654/2024 ISSN 2992-8869
84
omillar va ularning astma xurujlariga qanday ta’sir ko‘rsatishini aniqlash. Olingan
ma'lumotlar
asosida
davolash
taktikasini
optimallashtirish
va
individualizatsiyalangan davolash rejalarini ishlab chiqish.
Tadqiqot maqsadi:
Bolalarda bronxial astmaning klinik, immunologik va
mikrobiologik jihatlarini o‘rganish orqali kasallikni erta diagnostika qilish va
individual davolash yondashuvlarini ishlab chiqish.
Material va tadqiqot usullari:
Tadqiqot bolalarda bronxial astmaning klinik,
immunologik va mikrobiologik jihatlarini o‘rganish, shuningdek, davolash
taktikasini optimallashtirishga qaratilgan. Tadqiqot quyidagi usullar va materiallar
asosida amalga oshirildi:
Ishtirokchilar:
Tadqiqotda bronxial astma tashxisi
qo‘yilgan, 5 yoshdan 15 yoshgacha bo‘lgan 120 nafar bola ishtirok etdi. Bemorlar
og‘irlik darajasi va kasallik kechishiga qarab tasniflandi. Ishtirokchilar yengil,
o‘rtacha va og‘ir shakldagi astma bilan bo‘lgan bolalar guruhlariga ajratildi.
Klinik
tahlillar:
Klinik kuzatuvlar davomida bemorlarning astma belgilari, jumladan,
hansirash, yo‘tal va bronxial obstruksiya darajasi baholandi. Nafas olish faoliyatini
o‘lchash uchun spirometriya va peakflowmetr usullari qo‘llanildi. Kasallikning
kechishi, astma xurujlarining chastotasi va ular bilan bog‘liq omillar kuzatildi.
Immunologik tadqiqotlar:
Immunologik tekshiruvlar IgE darajasi va T-hujayralar
faolligini o‘lchash orqali amalga oshirildi. IgE antitanalari miqdori zardobdan
ELISA (enzimga bog‘liq immunosorbent tahlili) usuli bilan aniqlanib, immun
tizimining astma bilan bog‘liq reaktsiyalari tahlil qilindi. T-hujayralar faolligi
limfotsitlar yuzasidagi markerlarni aniqlash bilan baholandi.
Mikrobiologik
tahlillar:
Mikrobiologik jihatlar nafas yo‘llaridan olingan balg‘am va burun
suyuqliklaridan namuna olish orqali o‘rganildi. Ushbu namunalar bakteriologik va
virusologik tekshiruvlarga yuborildi, bunda bakteriyalarning o‘sishi va infektsiyalar
mavjudligi baholandi. Infektsiyalarning bronxial astma rivojlanishiga ta'siri aniqlash
uchun mikrobiota tarkibi va kasallik xurujlari orasidagi bog‘liqlik tahlil qilindi.
Statistik tahlil:
Olingan ma'lumotlar statistik dastur yordamida qayta ishlanib,
klinik, immunologik va mikrobiologik ko‘rsatkichlar o‘rtasidagi bog‘liqlik tahlil
qilindi. Natijalar statistik jihatdan ahamiyatli deb hisoblanishi uchun p<0.05 darajasi
qabul qilindi.
“JOURNAL OF SCIENCE-INNOVATIVE RESEARCH IN
UZBEKISTAN” JURNALI
VOLUME 2, ISSUE 9, 2024. SEPTEMBER
ResearchBib Impact Factor: 9.654/2024 ISSN 2992-8869
85
Natija:
Ushbu tadqiqotda 5 yoshdan 15 yoshgacha bo‘lgan 120 nafar bolada
bronxial astmaning klinik, immunologik va mikrobiologik aspektlari o‘rganildi.
Olingan natijalar asosida kasallikning og‘irlik darajasi, immunologik ko‘rsatkichlar
va mikrobiologik omillar orasidagi bog‘liqlik tahlil qilindi. Quyida natijalarning
asosiy jihatlari keltirilgan. Klinik natijalar: Astma belgilari bo‘yicha bolalar uch
guruhga bo‘lindi: yengil, o‘rtacha va og‘ir shakldagi astma. Har bir guruhdagi
bemorlarning xurujlari va bronxial obstruksiya darajasi spirometriya natijalari orqali
baholandi. (1-jadval)
(1-jadval)
Guruh
Bemorlar soni
Xurujlar soni (oyiga)
FEV1 (%)
Yengil
40
1-2
80-100
O‘rtacha
50
3-5
60-80
Og‘ir
30
>5
<60
Bu natijalar astma belgilari va xurujlar soni o‘rtasidagi bog‘liqlikni ko‘rsatadi.
Og‘ir shakldagi astmada xurujlar soni ko‘proq va bronxial obstruksiya darajasi
yuqoriroq bo‘lgani kuzatildi. Immunologik natijalar: Immunologik tahlillar IgE
antitanalari va T-hujayralar faolligini o‘lchash orqali amalga oshirildi. Natijalar
quyidagi jadvalda keltirilgan: (2-jadval)
(2-jadval)
Guruh
IgE darajasi (IU/ml)
T-hujayralar faolligi (%)
Yengil
150-300
35
O‘rtacha
300-600
50
Og‘ir
>600
70
Og‘ir astma shaklida IgE antitanalari darajasi va T-hujayralar faolligi sezilarli
darajada yuqori bo‘lib, bu immunologik mexanizmlarning kasallik rivojlanishidagi
rolini tasdiqlaydi.
“JOURNAL OF SCIENCE-INNOVATIVE RESEARCH IN
UZBEKISTAN” JURNALI
VOLUME 2, ISSUE 9, 2024. SEPTEMBER
ResearchBib Impact Factor: 9.654/2024 ISSN 2992-8869
86
Mikrobiologik natijalar
:
Mikrobiologik tahlillar nafas yo‘llaridan olingan
namunalar asosida amalga oshirildi. Olingan bakteriyalar va viruslar astma
xurujlarini kuchaytiruvchi omillar sifatida qayd etildi. (3-jadval)
(3-jadval)
Bakteriyalar / Viruslar
Xurujlar
soni
(oyiga)
Bemorlar
soni
(%)
Streptococcus
pneumoniae
3-5
40
Haemophilus influenzae
3-4
30
Rhinovirus
4-6
25
Tahlillar natijasida nafas yo‘llaridagi mikrobiologik infeksiyalar bronxial
astma xurujlarini kuchaytirishi aniqlangan. Ayniqsa, bakterial va virusli infeksiyalar
astma xurujlarining ko‘payishiga sabab bo‘lgan. Statistik tahlil
:
Olingan
ma'lumotlarning statistik tahlili shuni ko‘rsatdiki, klinik ko‘rsatkichlar,
immunologik faollik va mikrobiologik infeksiyalar o‘rtasida sezilarli bog‘liqlik
mavjud (p<0.05). Bu natijalar astmani samarali davolash uchun individual
yondashuvlar zarurligini tasdiqlaydi. Tadqiqot natijalari bolalarda bronxial
astmaning kompleks diagnostikasi va davolashni individualizatsiyalash zarurligini
ko‘rsatdi.
Xulosa:
Tadqiqot natijalari shuni ko‘rsatdiki, bolalarda bronxial astma klinik,
immunologik va mikrobiologik omillar bilan chambarchas bog‘liq. Klinik
ko‘rsatkichlarga ko‘ra, astmaning og‘ir shakllarida nafas yo‘llarining bronxial
obstruksiyasi kuchayishi va xurujlar soni ortishi kuzatildi. Immunologik tahlillar
astma og‘irlik darajasi bilan IgE antitanalari va T-hujayralar faolligi o‘rtasida
sezilarli bog‘liqlik mavjudligini aniqladi. Mikrobiologik tahlillar esa bakterial va
virusli infeksiyalar, xususan, Streptococcus pneumoniae, Haemophilus influenzae,
va Rhinovirus kabi mikroorganizmlar astma xurujlarini kuchaytiruvchi asosiy
omillar ekanligini tasdiqladi. Tadqiqot natijalari bolalarda bronxial astma
rivojlanishining kompleks va ko‘p omilli ekanligini ko‘rsatdi. Klinik, immunologik
va mikrobiologik ko‘rsatkichlar astmaning kechishini va davolashga bo‘lgan
yondashuvni belgilaydi. Og‘ir astma shaklida immunologik mexanizmlarning kuchli
“JOURNAL OF SCIENCE-INNOVATIVE RESEARCH IN
UZBEKISTAN” JURNALI
VOLUME 2, ISSUE 9, 2024. SEPTEMBER
ResearchBib Impact Factor: 9.654/2024 ISSN 2992-8869
87
faolligi va mikrobiologik infeksiyalar bilan bog‘liq xurujlarning kuchayishi
aniqlangan. Shu bois, kasallikning murakkabligini e'tiborga olgan holda individual
yondashuv va zamonaviy terapiya usullarini qo‘llash zarurligi ta'kidlandi. Tadqiqot
natijalariga asoslanib, bolalarda bronxial astmani samarali davolash uchun quyidagi
tavsiyalar beriladi: Immunoterapiya: Astma bilan kasallangan bolalarda IgE
darajasini kamaytirish va immun tizimining haddan tashqari faolligini nazorat qilish
uchun immunoterapiya qo‘llanishi kerak. Mikrobiologik boshqaruv: Bakterial va
virusli infeksiyalarni o‘z vaqtida aniqlash va ularni davolash astma xurujlarini
kamaytirish uchun muhim. Shuning uchun antibiotik va antivirus dorilarni maqsadli
qo‘llash tavsiya etiladi. Individualizatsiyalashgan davolash: Har bir bemorning
klinik, immunologik va mikrobiologik holatini hisobga olgan holda individual
davolash rejalarini ishlab chiqish zarur. Profilaktika: Bolalarda bronxial astmani
oldini olish uchun atrof-muhitni yaxshilash, allergenlar va infeksiyalardan
himoyalash choralari kuchaytirilishi kerak. Kelgusida bronxial astma bo‘yicha olib
boriladigan tadqiqotlar quyidagi yo‘nalishlarda davom ettirilishi tavsiya etiladi:
Genetik omillar: Bolalarda astmaning genetik asoslarini chuqur o‘rganish va
kasallikka moyillikni aniqlash bo‘yicha tadqiqotlar olib borish. Yangi davolash
usullari: Immunoterapiya va mikrobiologik boshqaruv bilan bog‘liq yangi
texnologiyalar va dori vositalarini tadqiq qilish, ularning samaradorligini klinik
sinovlarda tekshirish. Atrof-muhit omillari: Atrof-muhit, havoning ifloslanishi va
turmush tarzining astma rivojlanishiga ta'siri bo‘yicha keng qamrovli tadqiqotlarni
olib borish. Ushbu yo‘nalishlar bronxial astmaning kelgusida yanada samarali
davolash usullarini ishlab chiqish va kasallik xurujlarini kamaytirishga xizmat
qiladi.
Adabiyotlar ro’yxati:
1.
Global Initiative for Asthma (GINA). Global Strategy for Asthma
Management and Prevention. 2023 update.
2.
Agache, I., & Akdis, C. A. (2021). Precision medicine and asthma
biomarkers: challenges and opportunities. Allergy, 76(4), 1222-1235.
3.
Jackson, D. J., & Hartert, T. V. (2018). Asthma phenotypes and
endotypes: an evolving paradigm for classification. The Lancet, 392(10156), 2049-
2062.
“JOURNAL OF SCIENCE-INNOVATIVE RESEARCH IN
UZBEKISTAN” JURNALI
VOLUME 2, ISSUE 9, 2024. SEPTEMBER
ResearchBib Impact Factor: 9.654/2024 ISSN 2992-8869
88
4.
Reddel, H. K., Bateman, E. D., & Bousquet, J. (2018). Global Initiative
for Asthma (GINA) strategy: A roadmap for asthma control. European Respiratory
Journal, 51(5), 1702171.
5.
Fajt, M. L., & Wenzel, S. E. (2020). Asthma phenotypes and the use of
biologic medications in asthma treatment. Journal of Allergy and Clinical
Immunology: In Practice, 8(2), 461-466.
6.
Mukherjee, M., & Nair, P. (2017). Autoimmune responses in severe
asthma. Journal of Leukocyte Biology, 101(3), 635-641.
7.
Busse, W. W., & Lemanske, R. F. (2018). Advances in immunology:
Asthma. Journal of Allergy and Clinical Immunology, 142(6), 1411-1421.
8.
Peters, M. C., & Fahy, J. V. (2017). Metabolic consequences of obesity
as an "asthma endotype". The Journal of Allergy and Clinical Immunology: In
Practice, 5(6), 1574-1577.
9.
Fahy, J. V. (2020). Type 2 inflammation in asthma—present in most,
absent in many. Nature Reviews Immunology, 20(1), 57-68.
10.
Martinez, F. D., & Vercelli, D. (2019). Asthma. The Lancet,
392(10153), 1360-1372.
11.
Pavord, I. D., & Bush, A. (2018). Asthma: Time to redefine airways
diseases?. The Lancet, 391(10118), 297-299.
12.
Fitzpatrick, A. M., & Moore, W. C. (2019). Severe asthma phenotypes:
How should they guide evaluation and treatment?. The Journal of Allergy and
Clinical Immunology: In Practice, 7(3), 901-909.
13.
Schatz, M., Rosenwasser, L. J., & Busse, W. W. (2020). Asthma across
the ages: Adult asthma. Journal of Allergy and Clinical Immunology, 145(6), 1584-
1586.
14.
Castro, M., & Kraft, M. (2018). Update in asthma 2017. American
Journal of Respiratory and Critical Care Medicine, 197(3), 283-296.
15.
Wenzel, S. E. (2021). Treatment of severe asthma in adolescents and
adults. The New England Journal of Medicine, 384(13), 1287-1300.
16.
Menzies-Gow, A., Corren, J., & Bel, E. H. (2021). Biological therapies
in severe asthma: A European Respiratory Society/American Thoracic Society
guideline. European Respiratory Journal, 58(1), 2100058.
“JOURNAL OF SCIENCE-INNOVATIVE RESEARCH IN
UZBEKISTAN” JURNALI
VOLUME 2, ISSUE 9, 2024. SEPTEMBER
ResearchBib Impact Factor: 9.654/2024 ISSN 2992-8869
89
17.
Pavord, I. D., & Chanez, P. (2019). Emerging biologics in asthma:
Impact on phenotype, endotype, and outcomes. The Lancet Respiratory Medicine,
7(2), 120-128.
18.
Brusselle, G., & Bracke, K. (2019). Targeting immune pathways for the
treatment of severe asthma: Is there a future beyond type 2 inflammation?. The
Journal of Allergy and Clinical Immunology: In Practice, 7(6), 1810-1817.
19.
Kuruvilla, M. E., Lee, F. E., & Lee, G. B. (2019). Understanding asthma
phenotypes, endotypes, and mechanisms of disease. Clinical Reviews in Allergy &
Immunology, 56(2), 219-233.
20.
Masoli, M., Fabian, D., Holt, S., & Beasley, R. (2018). The global
burden of asthma: Executive summary of the GINA dissemination committee report.
European Respiratory Journal, 17(5), 143-151.
21.
Holguin, F., Cardet, J. C., Chung, K. F., & Khatri, S. (2019).
Management of severe asthma: A European Respiratory Society/American Thoracic
Society guideline. European Respiratory Journal, 54(2), 1900983.
22.
Castro-Rodriguez, J. A., & Holberg, C. J. (2020). Association of obesity
with asthma symptoms, exacerbations, and health care utilization. Annals of the
American Thoracic Society, 17(3), 322-329.
23.
Hinks, T. S. C., & Moffatt, M. F. (2020). Identifying type 2
inflammation in asthma. The Journal of Allergy and Clinical Immunology, 145(6),
1481-1493.
